{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:23:55Z","timestamp":1785335035743,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T00:00:00Z","timestamp":1595289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T00:00:00Z","timestamp":1595289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1208\/s12248-020-00478-5","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T22:03:38Z","timestamp":1595369018000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Application of Beta-Distribution and Combined Uniform and Binomial Methods in Longitudinal Modeling of Bounded Outcome Score Data"],"prefix":"10.1208","volume":"22","author":[{"given":"Chuanpu","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amarnath","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,21]]},"reference":[{"issue":"10","key":"478_CR1","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/psp4.12015","volume":"4","author":"RV Overgaard","year":"2015","unstructured":"Overgaard RV, Ingwersen SH, Tornoe CW. Establishing good practices for exposure-response analysis of clinical endpoints in drug development. CPT Pharmacometrics Syst Pharmacol. 2015;4(10):565\u201375.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"5","key":"478_CR2","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s10928-017-9534-0","volume":"44","author":"C Hu","year":"2017","unstructured":"Hu C, Zhou H, Sharma A. Landmark and longitudinal exposure-response analyses in drug development. J Pharmacokinet Pharmacodyn. 2017;44(5):503\u20137.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"478_CR3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/biostatistics\/kxj034","volume":"8","author":"E Lesaffre","year":"2007","unstructured":"Lesaffre E, Rizopoulos D, Tsonaka R. The logistic transform for bounded outcome scores. Biostatistics. 2007;8(1):72\u201385.","journal-title":"Biostatistics."},{"issue":"3","key":"478_CR4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/0091270009343695","volume":"50","author":"H Zhou","year":"2010","unstructured":"Zhou H, Hu C, Zhu Y, Lu M, Liao S, Yeilding N, et al. Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2010;50(3):257\u201367.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"478_CR5","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10928-017-9531-3","volume":"44","author":"C Hu","year":"2017","unstructured":"Hu C, Randazzo B, Sharma A, Zhou H. Improvement in latent variable indirect response modeling of multiple categorical clinical endpoints: application to modeling of guselkumab treatment effects in psoriatic patients. J Pharmacokinet Pharmacodyn. 2017;44(5):437\u201348.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"478_CR6","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s40300-016-0091-x","volume":"74","author":"MP Iannario","year":"2016","unstructured":"Iannario MP, D. A comprehensive framework of regression models for ordinal data. METRON. 2016;74(2):233\u201352.","journal-title":"METRON."},{"issue":"6","key":"478_CR7","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1208\/s12248-019-0370-6","volume":"21","author":"C Hu","year":"2019","unstructured":"Hu C. On the comparison of methods in analyzing bounded outcome score data. AAPS J. 2019;21(6):102.","journal-title":"AAPS J"},{"issue":"5","key":"478_CR8","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1177\/0962280216661370","volume":"27","author":"M Ursino","year":"2018","unstructured":"Ursino M, Gasparini M. A new parsimonious model for ordinal longitudinal data with application to subjective evaluations of a gastrointestinal disease. Stat Methods Med Res. 2018;27(5):1376\u201393.","journal-title":"Stat Methods Med Res"},{"issue":"3","key":"478_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1208\/s12248-020-00441-4","volume":"22","author":"C Hu","year":"2020","unstructured":"Hu C, Zhou H, Sharma A. Applying Beta distribution in analyzing bounded outcome score data. AAPS J. 2020;22(3):61.","journal-title":"AAPS J"},{"key":"478_CR10","doi-asserted-by":"crossref","unstructured":"Piccolo D, Simone R, Iannario M. Cumulative and CUB models for rating data: a comparative analysis. Int Stat Rev. 2019;87(2):207\u201336.","DOI":"10.1111\/insr.12282"},{"issue":"6","key":"478_CR11","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/BF02353483","volume":"24","author":"A Sharma","year":"1996","unstructured":"Sharma A, Jusko WJ. Characterization of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm. 1996;24(6):611\u201335.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"4","key":"478_CR12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10928-014-9366-0","volume":"41","author":"C Hu","year":"2014","unstructured":"Hu C, Szapary PO, Mendelsohn AM, Zhou H. Latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint. J Pharmacokinet Pharmacodyn. 2014;41(4):335\u201349.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"478_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s10928-007-9080-2","volume":"35","author":"MM Hutmacher","year":"2008","unstructured":"Hutmacher MM, Krishnaswami S, Kowalski KG. Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients. J Pharmacokinet Pharmacodyn. 2008;35:139\u201357.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"478_CR14","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1038\/psp.2014.15","volume":"3","author":"C Hu","year":"2014","unstructured":"Hu C. Exposure-response modeling of clinical end points using latent variable indirect response models. CPT Pharmacometrics Syst Pharmacol. 2014;3:e117.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"478_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s10928-015-9453-x","volume":"43","author":"C Hu","year":"2016","unstructured":"Hu C, Zhou H. Improvement in latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint in rheumatoid arthritis. J Pharmacokinet Pharmacodyn. 2016;43(1):45\u201354.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"478_CR16","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s10928-017-9529-x","volume":"44","author":"C Hu","year":"2017","unstructured":"Hu C, Adedokun OJ, Chen Y, Szapary PO, Gasink C, Sharma A, et al. Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn's disease. J Pharmacokinet Pharmacodyn. 2017;44(5):425\u201336.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"6","key":"478_CR17","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s10928-018-9610-0","volume":"45","author":"C Hu","year":"2018","unstructured":"Hu C, Adedokun OJ, Zhang L, Sharma A, Zhou H. Modeling near-continuous clinical endpoint as categorical: application to longitudinal exposure-response modeling of Mayo scores for golimumab in patients with ulcerative colitis. J Pharmacokinet Pharmacodyn. 2018;45(6):803\u201316.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"478_CR18","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s10928-018-9598-5","volume":"45","author":"C Hu","year":"2018","unstructured":"Hu C, Xu Y, Zhuang Y, Hsu B, Sharma A, Xu Z, et al. Joint longitudinal model development: application to exposure-response modeling of ACR and DAS scores in rheumatoid arthritis patients treated with sirukumab. J Pharmacokinet Pharmacodyn. 2018;45(5):679\u201391.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"478_CR19","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s10928-018-9581-1","volume":"45","author":"C Hu","year":"2018","unstructured":"Hu C, Yao Z, Chen Y, Randazzo B, Zhang L, Xu Z, et al. A comprehensive evaluation of exposure-response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis. J Pharmacokinet Pharmacodyn. 2018;45(4):523\u201335.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"478_CR20","unstructured":"Hu C, Zhou H, Sharma A. Facilitating longitudinal exposure-response modeling of a composite endpoint using the joint modeling of sparsely and frequently collected subcomponents. AAPS J. to appear."},{"issue":"6","key":"478_CR21","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMoa062382","volume":"356","author":"GG Krueger","year":"2007","unstructured":"Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, et al. A human interleukin-12\/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356(6):580\u201392.","journal-title":"N Engl J Med"},{"issue":"7","key":"478_CR22","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1177\/0091270008318670","volume":"48","author":"C Hu","year":"2008","unstructured":"Hu C, Zhou H. An improved approach for confirmatory phase III population pharmacokinetic analysis. J Clin Pharmacol. 2008;48(7):812\u201322.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"478_CR23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/pst.403","volume":"10","author":"C Hu","year":"2011","unstructured":"Hu C, Zhang J, Zhou H. Confirmatory analysis for phase III population pharmacokinetics. Pharm Stat. 2011;10(1):14\u201326.","journal-title":"Pharm Stat"},{"key":"478_CR24","doi-asserted-by":"crossref","unstructured":"Zhu Y, Hu C, Lu M, Liao S, Marini J, Yohrling J, et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting il-12\/23p40, in patients with moderate to severe plaque psoriasis, J Clin Pharmacol. 2009;49(2):162\u201375.","DOI":"10.1177\/0091270008329556"},{"issue":"9","key":"478_CR25","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/sim.4155","volume":"30","author":"MM Hutmacher","year":"2011","unstructured":"Hutmacher MM, French JL, Krishnaswami S, Menon S. Estimating transformations for repeated measures modeling of continuous bounded outcome data. Stat Med. 2011;30(9):935\u201349.","journal-title":"Stat Med"},{"issue":"1","key":"478_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s10928-012-9288-7","volume":"40","author":"C Hu","year":"2013","unstructured":"Hu C, Xu Z, Mendelsohn A, Zhou H. Latent variable indirect response modeling of categorical endpoints representing change from baseline. J Pharmacokinet Pharmacodyn. 2013;40(1):81\u201391.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"6","key":"478_CR27","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1023\/B:JOPA.0000012998.04442.1f","volume":"30","author":"L Zhang","year":"2003","unstructured":"Zhang L, Beal SL, Sheiner LB. Simultaneous vs. sequential analysis for population PK\/PD data I: best-case performance. J Pharmacokinet Pharmacodyn. 2003;30(6):387\u2013404.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"478_CR28","volume-title":"NONMEM user's guides (1989\u20132009)","author":"SL Beal","year":"2009","unstructured":"Beal SL, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM user's guides (1989\u20132009). Ellicott City: Icon Development Solutions; 2009."},{"key":"478_CR29","doi-asserted-by":"crossref","unstructured":"Bauer RJ. NONMEM tutorial part II: estimation methods and advanced examples. CPT Pharmacometrics Syst Pharmacol. 2019;8(8):538\u201356.","DOI":"10.1002\/psp4.12422"},{"key":"478_CR30","unstructured":"Karlsson MO, Holford NHG. A tutorial on visual predictive checks 2008 [updated 2008. Available from: www.page-meeting.org\/?abstract=1434."}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-020-00478-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-020-00478-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-020-00478-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T23:06:30Z","timestamp":1626822390000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-020-00478-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,21]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["478"],"URL":"https:\/\/doi.org\/10.1208\/s12248-020-00478-5","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,21]]},"assertion":[{"value":"25 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"95"}}